Clinical Trial Update: A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of docetaxel and carboplatin in late-relapse ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Paraplatin (Carboplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Conditions: Ovarian Epithelial Cancer Recurrent | Phase 2 | Status: COMPLETED